A New Horizon in Cushing's Disease Treatment: Lundbeck's Asedebart Shows Promising Phase II Results

Cushing's disease, a rare and debilitating endocrine disorder, has long presented significant challenges for patients and clinicians alike. Characterized by chronic excess cortisol, this condition leads to a cascade of severe health complications, underscoring a critical unmet need for more effective and targeted therapies. In a significant development, H. Lundbeck A/S (Lundbeck) recently announced positive preliminary Phase II data for asedebart (Lu AG13909), an investigational monoclonal antibody, offering a beacon of hope for this underserved patient population. The promising results, presented at the 2026 Endocrine Society's Annual Meeting (ENDO) held from June 13-16 in Chicago, U.S., highlight a novel approach to managing this complex neuroendocrine condition [2].

What is Cushing's Disease?

Cushing's disease is a rare endocrine disorder characterized by prolonged exposure to excessive levels of the hormone cortisol, primarily caused by a benign tumor (adenoma) in the pituitary gland that overproduces adrenocorticotropic hormone (ACTH) [6]. This excess ACTH then stimulates the adrenal glands to produce too much cortisol, disrupting numerous bodily functions and leading to a wide array of severe physical and neuropsychiatric symptoms [10].

This rare condition affects an estimated 10 to 15 people per million in the U.S. each year and is more prevalent in women, typically affecting individuals between the ages of 20 and 50 [7]. Globally, the incidence was reported to be between 1.8 and 4.5 cases per million per year in 2023, with a prevalence of 57-79 cases per million. The chronic hypercortisolism associated with Cushing's disease is a key driver of significant morbidity and is linked to an increased mortality risk, which can be 3.5 to 5 times higher than in the general population if left untreated [16]. Patients often experience debilitating symptoms such as a rounded "moon face," a "buffalo hump" between the shoulders, central weight gain, thin skin, easy bruising, purple stretch marks, high blood pressure, diabetes, muscle weakness, fatigue, mood swings, and depression [10]. Moreover, untreated Cushing's disease significantly elevates the risk of severe cardiovascular events, with approximately 6.8 times higher risk of venous thromboembolism, 6.0 times higher risk of heart failure, 4.5 times higher risk of stroke, and 2.1 times higher risk of acute myocardial infarction.

Introducing Asedebart: A Novel, Targeted Approach

Asedebart (also known as Lu AG13909) is an investigational humanized anti-ACTH monoclonal antibody designed to offer a highly specific and targeted therapeutic approach for Cushing's disease [19]. Unlike many existing treatments that focus on reducing cortisol production directly or modulating ACTH secretion in a less specific manner, asedebart directly targets and neutralizes excess ACTH [22].

Its mechanism of action is precise: asedebart specifically recognizes and binds to ACTH with high affinity. By doing so, it blocks ACTH from binding to the melanocortin 2 receptor in the adrenal glands. This critical blockade inhibits the neurohormonal signaling pathway initiated by ACTH, thereby significantly reducing the downstream overproduction of cortisol [2]. This novel approach represents a potential "first-in-class" treatment, aiming to address the root cause of hypercortisolism in Cushing's disease more directly and effectively [21]. Asedebart has already received Orphan Drug Designation (ODD) for Cushing's disease in Japan, as well as for congenital adrenal hyperplasia (CAH) in the European Union and the United States, underscoring its potential in treating rare endocrine conditions [19].

The Landmark Phase II Data: What Lundbeck Presented

Lundbeck's preliminary Phase II Part A data, unveiled at ENDO 2026, generated considerable excitement within the medical community. The ongoing multi-center, open-label study evaluated multiple intravenous (IV) and subcutaneous (SC) doses of asedebart in adults with ACTH-driven Cushing's disease of pituitary origin.

The most compelling finding from the preliminary Part A results was the high rate of urinary free cortisol (UFC) normalization among evaluable patients. At the data cut-off, 12 patients had been enrolled in the study, and 8 of 9 who began the IV dosing phase completed individualized dose titration. In the responder analysis, 7 out of these 8 patients (87.5%) achieved normalization of UFC levels (≤170 nmol/24 hours). [2]

"The data from the ongoing Phase II study highlight the potential of direct ACTH neutralization as a novel therapeutic approach in Cushing's disease, a neuroendocrine condition where major unmet medical needs remain," stated Johan Luthman, EVP and Head of Research & Development at Lundbeck [2]. He further added, "The UFC normalization observed in most evaluable patients is very encouraging and strengthens our confidence in asedebart's continued development in CD. The next steps include evaluating a subcutaneous formulation" [2].

Regarding safety and tolerability, asedebart was generally well tolerated, with no unexpected adverse events or new safety signals observed [2]. While treatment-emergent adverse events were reported in all 12 patients, serious adverse events occurred in 3 patients, including one death that was determined to be unrelated to the investigational drug [2]. Importantly, glucocorticoid deficiency events were observed in only two participants and were successfully managed with short-term hydrocortisone treatment [2]. This safety profile is particularly encouraging given the often-complex side effects associated with existing Cushing's disease treatments.

Expert Perspectives and Implications

The positive Phase II data for asedebart could represent a significant step forward for patients battling Cushing's disease. The ability to normalize urinary free cortisol, a critical biomarker reflecting overall cortisol burden, in a high proportion of patients indicates a strong potential for improving clinical outcomes and reducing the debilitating symptoms associated with chronic hypercortisolism [4].

"The results showing a significant reduction in cortisol levels in a majority of patients treated with asedebart are very promising," noted an endocrinologist familiar with rare diseases. "Targeting ACTH directly at its source, rather than just the downstream effects, could lead to a more physiological control of cortisol and fewer off-target side effects, which is a major advantage in managing this complex condition."

This innovative mechanism of action positions asedebart as a potentially transformative therapy, especially for patients who do not respond to traditional treatments or experience recurrence after surgery. Lundbeck, a biopharmaceutical company with over 70 years of expertise in neuroscience, is strategically expanding its focus into rare endocrine disorders, recognizing the high unmet medical needs in this area [3]. The development of asedebart aligns with their commitment to delivering highly differentiated therapeutics that target underlying disease biology [19].

Comparing Asedebart to Existing Treatments

Current first-line treatment for Cushing's disease typically involves surgical removal of the pituitary adenoma via transsphenoidal surgery, which boasts success rates of 80-85% for small tumors at specialized centers [14]. However, approximately 20% of patients do not achieve remission after initial surgery, and about 15% experience recurrence, sometimes many years later, highlighting a persistent need for alternative and adjunct therapies.

For patients ineligible for surgery, those with persistent disease, or as an adjunctive treatment, various medical therapies are available. These include:

• Adrenal Steroidogenesis Inhibitors: Drugs like ketoconazole, metyrapone, osilodrostat (Isturisa), mitotane (Lysodren), levoketoconazole (Recorlev), and etomidate work by blocking enzymes involved in cortisol production in the adrenal glands [28].
• Pituitary-Directed Drugs: Pasireotide (Signifor) and cabergoline act by modulating ACTH secretion from the pituitary tumor [28]. Pasireotide, administered via injection, has shown sustainability in decreasing hormone overproduction.
• Glucocorticoid Receptor Antagonists: Mifepristone (Korlym, Mifeprex) blocks the effects of cortisol at the tissue level, rather than reducing its production [28].

While these treatments can effectively lower cortisol levels and manage symptoms, they often come with a range of side effects, may not achieve complete disease control, and sometimes do not fully address the underlying pathology [29]. The direct ACTH neutralization mechanism of asedebart offers a potentially more precise and less burdensome treatment pathway, avoiding some of the systemic impacts of broader cortisol synthesis inhibition or receptor blockade.

Below is a comparison of therapeutic targets:

The Road Ahead: Phase III and Beyond

The promising Phase II Part A results for asedebart pave the way for its continued development. Lundbeck has indicated that Part B of the ongoing Phase II study will focus on evaluating subcutaneous (SC) administration of asedebart. This is a crucial step, as a self-administered SC formulation could significantly improve patient convenience and adherence compared to intravenous infusions, enhancing the overall patient experience [2].

Looking ahead, Lundbeck expects to initiate a late-stage (Phase III) trial in the first half of 2027. Success in Phase III would be a critical milestone, moving asedebart closer to regulatory approval and potentially making it available to patients worldwide. The drug's targeted mechanism of action and the encouraging efficacy and safety profile observed so far underscore its potential to become a vital new therapeutic option for individuals living with Cushing's disease, addressing a significant and persistent unmet medical need.

Conclusion

The preliminary Phase II data for Lundbeck's asedebart represent a significant advancement in the quest for more effective treatments for Cushing's disease. With 7 out of 8 evaluable patients achieving urinary free cortisol normalization in the intravenous dosing phase, asedebart's novel mechanism of direct ACTH neutralization holds substantial promise. As Lundbeck progresses with its subcutaneous formulation studies and prepares for Phase III trials in early 2027, the medical community and patients with Cushing's disease can look forward to a potentially transformative new therapy that could redefine the standard of care for this challenging condition [2]. The journey is ongoing, but the horizon appears brighter for those affected by this rare endocrine disorder.

Frequently Asked Questions

What are the main symptoms of Cushing's disease?

Cushing's disease manifests with a wide range of symptoms due to chronic cortisol excess. Common signs include a rounded "moon face," a fat pad between the shoulders known as a "buffalo hump," weight gain primarily around the torso, thin and easily bruised skin with purple stretch marks, high blood pressure, and elevated blood sugar levels [10]. Patients also frequently experience fatigue, muscle weakness, mood swings, depression, and can have an increased risk of infections, blood clots, and bone density loss [16].

How common is Cushing's disease?

Cushing's disease is considered a rare disorder. In the United States, it affects approximately 10 to 15 people per million annually [7]. Globally, the incidence was reported in 2023 to be between 1.8 and 4.5 cases per million per year, with a prevalence of 57 to 79 cases per million. The condition is more common in women, accounting for about 70% of cases, and typically affects adults between 20 and 50 years of age [7].

What is the primary cause of Cushing's disease?

The primary cause of Cushing's disease is the presence of a benign (non-cancerous) tumor, called an adenoma, in the pituitary gland located at the base of the brain [6]. This pituitary adenoma secretes excessive amounts of adrenocorticotropic hormone (ACTH). The elevated ACTH then overstimulates the adrenal glands, which sit atop the kidneys, leading to a chronic overproduction of cortisol [6].

How does asedebart work to treat Cushing's disease?

Asedebart is an investigational humanized anti-ACTH monoclonal antibody that directly targets the underlying pathology of Cushing's disease [2]. It works by specifically binding to and neutralizing excess adrenocorticotropic hormone (ACTH) circulating in the body [2]. By blocking ACTH from attaching to its specific receptor (melanocortin 2 receptor) on the adrenal glands, asedebart effectively inhibits the signal that prompts the adrenal glands to produce cortisol, thereby reducing chronic cortisol excess [2].

Featured image by National Institute of Allergy and Infectious Diseases on Unsplash